A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

NCT00617669 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1494

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel
DRUG: ZD4054
DRUG: Placebo

Sponsor

AstraZeneca